KalVista Pharmaceuticals, Inc.

NASDAQ:KALV

Biotechnology

Healthcare
$27.00 +0.00%

+$0.00 today

Market cap
$1.44B
Beta
-0.11
P/E (TTM)
-9.9
EPS (TTM)
-$2.74
52W Low $9.83High $27.00

Volume 4.26M

Average 3.47M

KALV Other Non-current Liabilities

Long-term obligations not reported separately, such as lease or pension liabilities.

KalVista Pharmaceuticals, Inc.NASDAQ: KALV

Other Non-current Liabilities · Q4 FY2026 · quarter ended Dec 2025

Other non-current liabilities of $119.06M in Q4 FY2026

Q4 FY2026 other non-current liabilities was $119.06M.

Context

  • Other non-current liabilities amounted to 35.5% of total assets at the end of Q4 FY2026.
  • Other non-current liabilities increased in 1 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterDec 2025
$119.06M— QoQ
Last fiscal yearDec 2025
$119.06M— YoY
Other Non-current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Non-current Liabilities history

USD · from the balance sheet

Latest · FY2026
119.06M USD
Year-over-year change
—

Other Non-current Liabilities vs competitors

How KALV compares with its peers on the latest reported figures

  • KALV's Dec 2025 other non-current liabilities of $119.06M is the 2nd highest of the 10 companies compared; the peer median is $491K.
  • Other non-current liabilities amounts to 35.5% of total assets for KALV, versus a peer median of 0.1%.
KALV Competitors Peer median
Other Non-current Liabilities for KALV and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ADCTADC Therapeutics S.A.Mar 2026$328.21M +7282.2%-75.4%112.6%
KALVKalVista Pharmaceuticals, Inc.Dec 2025$119.06M ——35.5%
OMEROmeros CorporationMar 2026$5.7M +26.7%+6.8%2.0%
OLMAOlema Pharmaceuticals, Inc.Mar 2026$3M ——0.6%
BCYCBicycle Therapeutics plcMar 2026$973K +201.2%-54.4%0.1%
FDMT4D Molecular Therapeutics, Inc.Mar 2026$491K -1.6%+28.6%0.1%
RIGLRigel Pharmaceuticals, Inc.Mar 2026$0 -100.0%—0.0%
PRTAProthena Corporation plcMar 2026$0 ——0.0%
VSTMVerastem, Inc.Mar 2026$0 -100.0%—0.0%
GOSSGossamer Bio, Inc.Mar 2026$0 ——0.0%
Peer median (excluding KALV) $491K+12.5%-23.8%0.1%

Competitors are the stored peer set for KALV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2022
Apr 2022
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
FY2026
Dec 2025
Cash & Equivalents30.73M56.24M31.79M98.64M229.34M
Short-term Investments135.47M93.14M178.61M89M70.87M
Net Receivables16.81M18.64M10.87M15.14M11.3M
Inventory00003.43M
Other Current Assets00019.21M0
Total Current Assets193.65M172.33M225.69M241.69M320.15M
Property, Plant & Equipment (Net)10.04M10.77M9.15M1.99M12.86M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets193K106K567K7.09M2.37M
Total Non-current Assets10.23M10.88M9.71M9.08M15.23M
Total Assets203.88M183.2M235.4M250.77M335.38M
Account Payables3.64M4.82M9.11M4.88M8.27M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00011M0
Other Current Liabilities4.17M4.21M6.69M036.8M
Total Current Liabilities11.58M15.03M22.81M45.17M57.36M
Long-term Debt0000139.23M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)000105.88M11.71M
Other Non-current Liabilities0000119.06M
Total Non-current Liabilities7.21M7.15M6.02M110.21M280.73M
Total Liabilities18.79M22.18M28.82M155.38M338.09M
Common Stock25K34K42K50K51K
Retained Earnings(250.18M)(343.08M)(469.73M)(653.17M)(762.69M)
Accumulated OCI(3.86M)(3.06M)(3.49M)(5.21M)(7.13M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity185.09M161.03M206.58M95.39M(2.71M)
Total Debt8.19M8.23M7.32M6.31M151.58M
Net Debt(22.54M)(48.01M)(24.47M)(92.34M)(77.77M)

KalVista Pharmaceuticals, Inc.

NASDAQ:KALV

Intrinsic Alpha fair value

Locked

Current Price

$27.00

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.